Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 12/20 | 0.58 |
| ▸ | FAP | Q12884 | 2/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13360612 | 0.88 | CYP3A4 (0.56) | CYP3A4FAPADORA2AADORA1CYP2D6 | |
| SCHEMBL13983477 | 0.87 | CYP3A4 (0.76) | CYP3A4FAPCYP2D6 | |
| SCHEMBL7267656 | 0.87 | CYP3A4 (0.76) | CYP3A4FAPCYP2D6 | |
| SCHEMBL7268779 | 0.87 | CYP3A4 (0.76) | CYP3A4FAPCYP2D6 | |
| SCHEMBL14629613 | 0.86 | CYP3A4 (0.65) | CYP3A4FAPADORA2AADORA1CYP2D6 | |
| SCHEMBL13360654 | 0.82 | HSP90AB1 (0.44) | CYP3A4CYP2D6 | |
| SCHEMBL13411861 | 0.79 | CYP3A4 (0.57) | CYP3A4FAPADORA2AADORA1CYP2D6 | |
| SCHEMBL12445668 | 0.78 | FGFR1 (0.69) | CYP3A4FAPADORA2AADORA1FGFR1 | |
| SCHEMBL14669197 | 0.78 | CYP3A4 (0.74) | CYP3A4FAPADORA2AADORA1CYP2D6 | |
| SCHEMBL14037141 | 0.77 | CYP3A4 (0.58) | CYP3A4FAPADORA2AADORA1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723319-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2010-05-25 | — | — | US | disclosed |
| US-20100004440-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2010-01-07 | — | — | US | disclosed |
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004440-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | CYP3A4 456/4885FAP 2016/4885ADORA2A 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.